The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 353:2392-2394 December 1, 2005 Number 22
NextNext

Scaling Up Treatment — Why We Can't Wait
Jim Yong Kim, M.D., Ph.D., and Charlie Gilks, D.Phil., F.R.C.P.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Severe, P.
-PubMed Citation
Many arguments have been raised over the years to justify not moving rapidly forward with antiretroviral treatment programs for people living with the human immunodeficiency virus (HIV) and AIDS in settings with limited resources. The standard litany included the price of therapy as compared with the poverty of the patient, the complexity of the intervention, the lack of infrastructure for laboratory monitoring, and the staggering lack of trained health care providers. Narrow cost-effectiveness arguments have been commonplace. False dichotomies — prevention or treatment, rather than both — have too often gone unchallenged. Perhaps of greatest concern several years ago was . . . [Full Text of this Article]


Source Information

From the HIV/AIDS Department, World Health Organization, Geneva.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.